Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Expected to Post Earnings of $0.07 Per Share

Share on StockTwits

Wall Street analysts expect Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) to announce $0.07 earnings per share for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Vanda Pharmaceuticals’ earnings, with the highest EPS estimate coming in at $0.12 and the lowest estimate coming in at $0.02. Vanda Pharmaceuticals reported earnings per share of $0.20 during the same quarter last year, which would indicate a negative year over year growth rate of 65%. The company is expected to issue its next quarterly earnings report on Wednesday, November 6th.

According to Zacks, analysts expect that Vanda Pharmaceuticals will report full year earnings of $0.32 per share for the current fiscal year, with EPS estimates ranging from $0.27 to $0.35. For the next financial year, analysts expect that the company will post earnings of $0.82 per share, with EPS estimates ranging from $0.20 to $1.75. Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that cover Vanda Pharmaceuticals.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings results on Wednesday, July 31st. The biopharmaceutical company reported $0.21 EPS for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.24. The business had revenue of $59.06 million during the quarter, compared to analyst estimates of $54.19 million. Vanda Pharmaceuticals had a return on equity of 10.23% and a net margin of 13.61%. Vanda Pharmaceuticals’s quarterly revenue was up 24.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.15 EPS.

VNDA has been the subject of a number of recent analyst reports. Zacks Investment Research raised Vanda Pharmaceuticals from a “hold” rating to a “buy” rating and set a $14.00 price target for the company in a research report on Friday, August 2nd. ValuEngine raised Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Oppenheimer set a $18.00 target price on Vanda Pharmaceuticals and gave the stock a “hold” rating in a research report on Sunday, May 5th. Stifel Nicolaus reissued a “hold” rating and issued a $17.00 target price on shares of Vanda Pharmaceuticals in a research report on Wednesday, July 31st. Finally, Citigroup raised Vanda Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $19.00 target price for the company in a research report on Thursday, August 1st. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and four have given a buy rating to the company. Vanda Pharmaceuticals has a consensus rating of “Hold” and an average target price of $26.57.

In related news, CEO Mihael Hristos Polymeropoulos sold 72,872 shares of the company’s stock in a transaction that occurred on Tuesday, May 21st. The stock was sold at an average price of $15.34, for a total value of $1,117,856.48. Following the sale, the chief executive officer now owns 1,276,343 shares in the company, valued at approximately $19,579,101.62. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 8.20% of the company’s stock.

Several institutional investors have recently bought and sold shares of the stock. Advisor Group Inc. boosted its holdings in shares of Vanda Pharmaceuticals by 66.2% in the 4th quarter. Advisor Group Inc. now owns 2,916 shares of the biopharmaceutical company’s stock worth $77,000 after purchasing an additional 1,161 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Vanda Pharmaceuticals by 104.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 530,705 shares of the biopharmaceutical company’s stock worth $13,867,000 after purchasing an additional 270,795 shares in the last quarter. Amalgamated Bank purchased a new position in shares of Vanda Pharmaceuticals in the 4th quarter worth about $214,000. Geode Capital Management LLC boosted its holdings in shares of Vanda Pharmaceuticals by 1.1% in the 4th quarter. Geode Capital Management LLC now owns 596,626 shares of the biopharmaceutical company’s stock worth $15,588,000 after purchasing an additional 6,666 shares in the last quarter. Finally, Strs Ohio boosted its holdings in shares of Vanda Pharmaceuticals by 28.4% in the 1st quarter. Strs Ohio now owns 42,500 shares of the biopharmaceutical company’s stock worth $782,000 after purchasing an additional 9,400 shares in the last quarter. Institutional investors own 99.33% of the company’s stock.

VNDA opened at $15.05 on Friday. The firm’s 50 day simple moving average is $13.85. The company has a market cap of $801.77 million, a price-to-earnings ratio of 31.35 and a beta of 0.38. Vanda Pharmaceuticals has a one year low of $11.83 and a one year high of $33.44.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.

Further Reading: Outstanding Shares

Get a free copy of the Zacks research report on Vanda Pharmaceuticals (VNDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Euronav NV  Shares Sold by Doheny Asset Management CA
Euronav NV Shares Sold by Doheny Asset Management CA
Evercore Wealth Management LLC Decreases Stock Position in Stryker Co.
Evercore Wealth Management LLC Decreases Stock Position in Stryker Co.
Sherwin-Williams Co  Holdings Raised by Evercore Wealth Management LLC
Sherwin-Williams Co Holdings Raised by Evercore Wealth Management LLC
Evercore Wealth Management LLC Acquires 3,118 Shares of PepsiCo, Inc.
Evercore Wealth Management LLC Acquires 3,118 Shares of PepsiCo, Inc.
Doheny Asset Management CA Sells 800 Shares of ConocoPhillips
Doheny Asset Management CA Sells 800 Shares of ConocoPhillips
iCAD  Upgraded at ValuEngine
iCAD Upgraded at ValuEngine


© 2006-2019 Ticker Report